UPLC-MS/MS检测大鼠体内达卢生坦的血药浓度及其药动学研究

    Study on Plasma Concentration and Pharmacokinetics of Darusentan in Rat Plasma by UPLC-MS/MS

    • 摘要: 目的 建立一种快速、高灵敏度和高选择性的UPLC-MS/MS用于大鼠血浆中达卢生坦的测定。方法 通过蛋白沉淀法完成血浆样品处理。通过Acquity UPLC BEH C18柱(2.1 mm×50 mm,1.7 μm)色谱柱,流动相为0.1%甲酸水-乙腈,流速为0.4 mL·min-1。采用ESI+方式检测,扫描方式为多反应离子监测方式检测。结果 达卢生坦血药浓度在0.01~2.5 μg·mL-1内线性关系良好(R2>0.999 6),定量下限(LLOQ)为0.01 μg·mL-1。血浆中的达卢生坦平均回收率为87.613%~97.115%,日内及日间精密度RSD<7.71%,基质效应RSD<9.34%。结论 该方法灵敏高,快速高效,能成功应用于大鼠口服10.0 mg·kg-1达卢生坦后的药动学研究。

       

      Abstract: OBJECTIVE To develop a rapid, highly sensitive and selective UPLC-MS/MS for the determination of darusentan in rat plasma. METHODS Plasma samples were processed by protein precipitation. The separation was achieved by a gradient mobile phase, consisting of an aqueous solution of 0.1% formic acid and acetonitrile using an Acquity UPLC BEH C18 column (2.1 mm×50 mm, 1.7 μm). The flow rate was 0.4 mL·min-1. ESI+ was used to detect. The scanning mode was MRM. RESULTS The standard curve was linear over the range of 0.01-2.5 μg·mL-1(R2>0.999 6) with a LLOQ of 0.01 μg·mL-1. The average recovery of darusentan in plasma was 87.613%-97.115%. The RSD of intra-and inter-assay precision andaccuracy were <7.71%. The RSD of matrix effect was <9.34%. CONCLUSION This method is successfully applied in pharmacokinetic study after oral administration of 10.0 mg·kg-1 darusentan in rats.

       

    /

    返回文章
    返回